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Introduction
Combining endocrine therapies for breast cancer with various
targeted biological therapies has become a very active area
of clinical research aimed at overcoming or preventing
endocrine resistance. Several theories, each supported by
preclinical and - in some instances - clinical data, have been
proposed to explain both the acquired and de novo endo-
crine resistant phenotype that is observed in oestrogen
receptor (ER)-positive breast cancer [1]. These include
mechanisms whereby there is a sustained dependence on
ER-mediated signalling despite resistance to an individual
endocrine agent, and various gene silencing mechanisms that
cause reversible suppression of ER activity. Still other mecha-
nisms involve acquired changes in peptide growth factor
mediated mitogenic signalling pathways, which may or may
not crosstalk with existing ER-signalling pathways. For
example, it is known that activation of signalling via the human
epidermal growth factor receptor (HER) family (namely
epidermal growth factor receptor [EGFR] and HER2) can
amplify existing endocrine signalling within ER-positive breast
cancer cells, thus bypassing the inhibitory effects of any anti-
oestrogen such as tamoxifen [2] or oestrogen deprivation
therapy [3]. This in turn manifests clinically as endocrine
resistance. However, in clinical practice the strong likelihood
is that, for ER-positive breast cancer at least, no single uni-
fying mechanism for endocrine resistance will be discovered.
Therefore, identifying which resistance mechanism is opera-
tional in an individual patient could become clinically relevant
to tailoring the subsequent therapy.
Current clinical trials have investigated three approaches to
overcoming endocrine resistance, including maximal block-
ade of ER signalling, combinations of endocrine therapy with
novel therapies that target the HER family of growth factor
receptors, and combinations with drugs that target relevant
downstream signalling pathways. Not all approaches have
been successful to date, despite often very encouraging
preclinical data. As discussed below, various issues in
appropriate clinical trial design and patient selection must be
addressed in order to maximize the potential of this new
integrated approach.
Maximal blockade of oestrogen receptor
signalling
Given the published evidence for retention of a functional ER
pathway after acquired resistance to tamoxifen/oestrogen
deprivation therapy, one strategy has been to develop endo-
crine therapies that deliver maximal ER signalling blockade.
Fulvestrant is a novel type of ER antagonist that prevents ER
dimerization and leads to rapid degradation of the fulvestrant-
ER complex, producing loss of cellular ER [4]. It has been
shown that, because of its unique mechanism of action,
fulvestrant delays the emergence of acquired resistance com-
pared with tamoxifen in an MCF-7 hormone-sensitive xeno-
graft model [5]. Clinical data from phase II studies in post-
menopausal women with advanced breast cancer suggested
some modest efficacy for fulvestrant in a second/third-line
setting [6-8]. This was confirmed in the large randomized
phase III EFECT (Evaluation of Faslodex versus Exemestane
Clinical Trial) study [9], which demonstrated similar efficacy
for fulvestrant versus exemestane in patients who have
progressed on treatment with nonsteroidal aromatase
inhibitors (AIs) [9].
Laboratory evidence has suggested that the efficacy of
fulvestrant - especially in the setting of endocrine resistance,
where activated ER signalling may still be dominant - could
critically depend on the background oestrogen environment
in which the cells exist. This has led to the concept that ER-
positive endocrine resistant cells may need maximal ER
signalling blockade.
Recent experiments with tamoxifen-stimulated breast cancer
xenografts demonstrated paradoxical effects on tumour growth,
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which depended on whether fulvestrant was administered in
the presence or absence of oestradiol [10]. Similar findings
have been reported in cells resistant to long-term oestrogen
deprivation, in which maximal growth inhibition of cells was
observed with a dose of 10-8 mol/l fulvestrant, but the titration
back of increasing amounts of oestradiol resulted in re-
growth of cells that fulvestrant was no longer able to
antagonize effectively [11]. In addition, in a xenograft model,
combined therapy with letrozole plus fulvestrant was signifi-
cantly more effective than either agent alone, delaying
emergence of resistance [12]. On the basis of these findings,
an ongoing phase III trial (SoFEA [Study of Faslodex versus
Exemestane with/without Arimidex]) will compare progression-
free survival in patients who have progressed on a
nonsteroidal AI, and who are subsequently treated with either
fulvestrant plus continued anastrozole or with fulvestrant
alone. A further first-line phase III study (FACT [Fulvestrant
and Anastrozole Clinical Trial]) has compared anastrozole
plus fulvestrant versus anastrozole alone in endocrine
sensitive advanced breast cancer. These trials will hopefully
address the issue of whether maximal hormonal blockade
(total ligand deprivation plus complete ER downregulation)
will better treat or prevent endocrine resistance.
Co-targeting ER and HER family signalling:
prevention of acquired resistance
Based on the preclinical evidence and rationale for co-
targeting ER and HER family signalling, a number of trials
have been conducted with either the HER2 monoclonal
antibody trastuzumab or the EGFR/HER2 tyrosine kinase
inhibitors gefitinib, erlotinib or lapatinib in combination with
endocrine therapy [13]. Some of these trials were conducted
in patients with established hormonal resistance, in which
activated growth factor pathways may be operative. However,
many were conducted in the first-line setting in ER-positive
hormone-sensitive patients, and treatment was combined
with an AI (clinical and experimental data have shown that
tyrosine kinase inhibitors alone may have limited activity in this
setting). Therefore, the primary end-point for these trials was
to investigate whether time to disease progression can be
significantly prolonged by the addition to endocrine treatment
of a targeted therapy, thus delaying the emergence of
resistance, as demonstrated in the various preclinical models
described above.
Three key randomized studies in advanced breast cancer
have been reported to date. A double-blind, placebo-con-
trolled phase II trial of tamoxifen with/without gefitinib as first-
line endocrine therapy was conducted in 290 postmeno-
pausal women with ER-positive metastatic breast cancer
[14]. This study set out to test the preclinical concept that
combination therapy could delay the onset of acquired
resistance to endocrine therapy, as demonstrated both in
vitro and in xenograft models in vivo [2,3]. Disease was either
endocrine naïve or had developed more than a year after
completion of adjuvant tamoxifen (stratum 1; n = 206), or it
had developed during or after AI therapy (stratum 2; n = 84).
In stratum 1 (endocrine naïve) there was a numerical increase
in progression-free survival (PFS) from 10.9 to 8.8 months
(hazard ratio = 0.84, 95% confidence interval = 0.59 to 1.18;
P = 0.31), which met the predefined criterion of a 5%
improvement in PFS. Patients who had been pre-exposed to
AIs did not gain any benefit from the combination, suggesting
that patient characteristics are crucial in selecting an
appropriate population in which to test these therapies.
The first results of a second randomized trial of gefitinib and
anastrozole versus anastrazole alone, conducted in a similar
first-line patient population of women with ER-positive
advanced breast cancer, were reported at the American
Society of Clinical Oncology meeting in June 2008 [15].
There was a significant prolongation of PFS from a median of
8.2 months with anastrozole to 14.6 months with the
combination (hazard ratio = 0.55, 95% confidence interval =
0.32 to 0.94). The number of patients in this second study
was only 93, and no information was available on how many
patients had received prior adjuvant endocrine therapy, and
therefore which patients derived benefit from the combina-
tion. This will be important information, especially given that in
both gefitinib studies there was no improvement in objective
response rates (initial tumour shrinkage was no greater for
the combination). However, a numerical improvement in
clinical benefit rate seen in both studies (inclusion of patients
with stable disease) implies that any clinical gain exists by
delaying resistance, probably in those with initial endocrine-
sensitive ER-positive disease, as first demonstrated in both in
vitro and xenograft models for the addition of gefitinib to
endocrine therapy [2,3].
Likewise, targeting HER2 in hormone-receptor positive breast
cancer has been explored as a means of improving endocrine
responsiveness. This may involve re-expression of silenced
ER, as outlined in the preclinical data [16]. Indeed, there is
clinical evidence - from a series of 10 patients with ER-
negative/HER2-positive advanced breast cancer who had
serial biopsies during trastuzumab therapy [17] - that
trastuzumab can restore both ER expression and endocrine
responsiveness. A phase II clinical trial of letrozole and the
monoclonal antibody trastuzumab in patients with ER-
positive/HER2-positive metastatic breast cancer revealed
that the combination was well tolerated and had a clinical
benefit rate (partial response + stable disease) of 50% [18].
Subsequently, a randomized phase II trial conducted in 207
patients with known ER-positive/HER2-positive metastatic
breast cancer recently reported a doubling of PFS with the
addition of trastuzumab over anastrozole alone (4.8 months
versus 2.4 months; P = 0.0016) [19]. Lapatinib, a potent oral
tyrosine kinase inhibitor of both EGFR and HER2, has since
been explored in combination with endocrine therapy based
on  in vitro data demonstrating that oestrogen deprivation
significantly enhances the anti-proliferative effects of lapatinib
in HER2-amplified breast cancer cell lines [20,21]. Similarly,Page 3 of 5
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preclinical evidence suggests that lapatinib can significantly
enhance sensitivity to tamoxifen in cell lines with acquired
tamoxifen resistance [22].
A phase III trial has completed recruitment of 1,200 patients
with metastatic ER-positive breast cancer who were randomly
assigned to receive either letrozole alone or letrozole
combined with lapatinib. This large study may offer an
important insight into the subgroups of patients who are most
likely to benefit from a lapatinib-endocrine combination, such
as known ER-positive/HER2-positive breast cancer with
potential de novo endocrine resistance (at least 200 such
patients were included in the study), or ER-positive/HER2-
negative tumours that might develop acquired resistance to
letrozole during treatment because of adaptive EGFR or
HER2 upregulation. To identify the latter, all patients had
serum taken at baseline entry for assessment of circulating
extracellular domain HER2, which has been reported to be a
predictor of poorer outcome with endocrine therapy, with
seroconversion occurring during endocrine therapy in up to
25% of patients with ER-positive metastatic disease treated
with either letrozole or tamoxifen [23]. Thus, correlative
biomarker studies will be crucial to the interpretation of which
patients with ER-positive tumors may derive benefit from
combined targeted therapy with endocrine treatment.
Targeting downstream signalling
Other intracellular pathways downstream from cell surface
growth factor receptors may become operative in endocrine
resistance and may thus be appropriate targets for combi-
nation therapy strategies. The phosphoinositide-3 kinase
(PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway
is activated by a number of growth factors, including insulin,
insulin-like growth factor I, basic fibroblast growth factor,
epidermal growth factor and vascular endothelial growth
factor. Mutations in the catalytic domain of PI3K have been
identified in 20% to 25% of breast cancers [24,25]. Although
PI3K inhibitors are still in the early stages of development,
mTOR inhibitors have been tested in breast cancer in
combination with endocrine therapies. A randomized phase II
study of letrozole alone or in combination with the mTOR
inhibitor temsirolimus suggested a modest benefit from the
combination in terms of median PFS (13.2 months versus
11.6 months) [26]. Unfortunately, the resulting large phase III
randomized trial of letrozole alone or in combination with
temsirolimus in 992 postmenopausal women was terminated
early after an interim analysis demonstrated a lack of benefit
from the combination [27]. It is probable that inability to
identify patients in whom the tumours exhibit dependence on
PI3K/mTOR activation severely limited the likelihood of
demonstrating benefit in this large phase III trial. Likewise,
concern has been expressed that mTOR inhibition may
induce a feedback loop via S6kinase and insulin-like growth
factor receptor, which enhances further Akt activation, thus
overcoming the effects of mTOR inhibition. Thus, an under-
standing of adapative escape pathways is also critical to
utilizing targeted therapies effectively, because - ultimately -
vertical combinations of more than one key signal trans-
duction inhibitors in combination with endocrine treatments
may prove to be more effective.
More recent studies conducted in the neoadjuvant setting
have evaluated the benefit of adding the mTOR inhibitor
everolimus to letrozole. In a randomized phase II study
conducted in 270 postmenopausal women with ER-positive
primary operable breast cancer (>2 cm in size), the
combination of letrozole and everolimus for 4 months before
surgery resulted in significantly greater tumour shrinkage, as
judged by ultrasound (58% versus 47%; P = 0.03), and a
greater reduction in cell proliferation, as measured by changes
in Ki-67 after 15 days therapy [28]. In associated biomarker
studies to identify those tumours that are most likely to
respond to combined mTOR antagonists and AI, elevated
levels of one of the downstream biomarkers of mTOR
activation (pS6240 kinase) was associated with a greater
likelihood of response to the combination (odds ratio = 2.1)
[29]. These types of clinical studies in primary breast cancer
can yield informative biomarker data on those tumours that
are more likely to respond better ‘up front’ to the combination,
but they may be more limited in predicting which tumours
then utilize the given downstream signalling pathway during
prolonged endocrine therapy as a means of developing
acquired endocrine resistance.
Future challenges
There is an increasing body of evidence that suggests that
ER signalling survives, and that growth factor receptor and
downstream kinases often operate in conjunction with ER
through bidirectional crosstalk to account for both de novo
and acquired endocrine resistance. The nature of the
interaction between ER and mitogenic signalling probably
varies over time and from one patient to another. Despite the
strong preclinical data and rationale, translation of these
hormone-resistance hypotheses into successful clinical
studies of combined targeted therapies and endocrine treat-
ments have yielded varied results to date. This may in part be
attributable to poor selection of patients, lack of stratification
for prior endocrine responsiveness, inappropriate clinical
end-points and an incomplete understanding of whether the
given target is an ‘addictive’ component in the cell. In other
words, it is unlikely that patients will respond to combina-
tions with specific inhibitors unless the intended target is a
significant driver of endocrine-resistant growth. Thus,
biological analyses are still required to shed further light on
the clinically relevant mechanisms of endocrine resistance
that operate in individual patients, because these may
ultimately show us the most intelligent way to combat the
various hormone-resistance pathways that ER-positive
breast cancer cells utilize to survive.
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